BRPI0821373B8 - composições farmacêuticas contendo ao menos um princípio ativo protéico protegido de enzimas digestivas - Google Patents

composições farmacêuticas contendo ao menos um princípio ativo protéico protegido de enzimas digestivas

Info

Publication number
BRPI0821373B8
BRPI0821373B8 BRPI0821373A BRPI0821373A BRPI0821373B8 BR PI0821373 B8 BRPI0821373 B8 BR PI0821373B8 BR PI0821373 A BRPI0821373 A BR PI0821373A BR PI0821373 A BRPI0821373 A BR PI0821373A BR PI0821373 B8 BRPI0821373 B8 BR PI0821373B8
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
protein active
compositions containing
digestive enzymes
active ingredient
Prior art date
Application number
BRPI0821373A
Other languages
English (en)
Inventor
Bennis Farid
Serrano Jean-Jacques
Original Assignee
Bennis Farid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bennis Farid filed Critical Bennis Farid
Publication of BRPI0821373A2 publication Critical patent/BRPI0821373A2/pt
Publication of BRPI0821373B1 publication Critical patent/BRPI0821373B1/pt
Publication of BRPI0821373B8 publication Critical patent/BRPI0821373B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

composições farmacêuticas contendo ao menos um princípio ativo protéico protegido de enzimas digestivas. a presente invenção se refere a composições farmacêuticas que contenham ao menos um princípio ativo protéico protegido de enzimas digestivas. as referidas composições farmacêuticas contêm ao menos um referido princípio ativo protéico, na forma livre, assim como, quando líquidas, um sistema capaz de tamponá-las em um ph maior do que 4 e menor ou igual a 8, ou, quando sólidas, um sistema que exerça, quando elas forem colocada em um meio líquido, um efeito tampão entre um ph maior do que 4 e menor ou igual a 8.
BRPI0821373A 2007-12-19 2008-12-18 composições farmacêuticas contendo ao menos um princípio ativo protéico protegido de enzimas digestivas BRPI0821373B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0759971A FR2925333B1 (fr) 2007-12-19 2007-12-19 Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives
PCT/FR2008/052357 WO2009083686A1 (fr) 2007-12-19 2008-12-18 Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives

Publications (3)

Publication Number Publication Date
BRPI0821373A2 BRPI0821373A2 (pt) 2015-06-16
BRPI0821373B1 BRPI0821373B1 (pt) 2020-04-22
BRPI0821373B8 true BRPI0821373B8 (pt) 2021-05-25

Family

ID=39671377

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0821373A BRPI0821373B8 (pt) 2007-12-19 2008-12-18 composições farmacêuticas contendo ao menos um princípio ativo protéico protegido de enzimas digestivas

Country Status (19)

Country Link
US (1) US8309123B2 (pt)
EP (1) EP2234598A1 (pt)
JP (1) JP5676272B2 (pt)
KR (2) KR20150132887A (pt)
CN (1) CN101917967B (pt)
AP (1) AP3573A (pt)
AR (1) AR069847A1 (pt)
AU (1) AU2008345474B2 (pt)
BR (1) BRPI0821373B8 (pt)
CA (1) CA2709899C (pt)
EA (1) EA023107B1 (pt)
FR (1) FR2925333B1 (pt)
HK (1) HK1146386A1 (pt)
IL (1) IL206364A (pt)
MA (1) MA31927B1 (pt)
MX (1) MX2010006927A (pt)
TN (1) TN2010000290A1 (pt)
TW (1) TWI461226B (pt)
WO (1) WO2009083686A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120035103A1 (en) * 2010-01-29 2012-02-09 Pillion Dennis J Method for administration of insulin and pharmaceutical composition thereof
WO2015166473A1 (en) 2014-05-01 2015-11-05 Sun Pharmaceutical Industries Limited Extended release suspension compositions
US9962336B2 (en) 2014-05-01 2018-05-08 Sun Pharmaceutical Industries Limited Extended release suspension compositions
US10258583B2 (en) 2014-05-01 2019-04-16 Sun Pharmaceutical Industries Limited Extended release liquid compositions of guanfacine
US20180104197A9 (en) 2014-05-01 2018-04-19 Sun Pharmaceutical Industries Limited Extended release liquid compositions of metformin
MX2017001332A (es) 2014-07-30 2017-08-02 Sun Pharmaceutical Ind Ltd Envase con camara.doble.
RU2746548C2 (ru) 2014-11-04 2021-04-15 Иннофармакс, Инк. Пероральное введение неустойчивых или плохо всасывающихся лекарственных средств
US10369078B2 (en) 2016-05-02 2019-08-06 Sun Pharmaceutical Industries Limited Dual-chamber pack for pharmaceutical compositions
US10238803B2 (en) 2016-05-02 2019-03-26 Sun Pharmaceutical Industries Limited Drug delivery device for pharmaceutical compositions
FR3120189A1 (fr) * 2021-03-01 2022-09-02 Farid Bennis Composition pharmaceutique pour une administration par voie orale d’un agoniste du récepteur du GLP-1

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE36225B1 (en) 1971-01-28 1976-09-15 Nat Res Dev Improvements relating to insulin derivatives
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
WO1985005029A1 (en) 1984-05-09 1985-11-21 Medaphore Inc. Oral insulin and a method of making the same
US4693433A (en) * 1986-06-06 1987-09-15 Merrill David Martin Unwind stand for web rolls
US6191105B1 (en) * 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
GB9417524D0 (en) * 1994-08-31 1994-10-19 Cortecs Ltd Pharmaceutical compositions
EP0781142A4 (en) * 1994-09-01 2003-04-09 Allied Medical Res Associates COMPOSITIONS AND METHOD FOR PROVIDING POLYPEPTIDES
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
US5912014A (en) * 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US6071539A (en) * 1996-09-20 2000-06-06 Ethypharm, Sa Effervescent granules and methods for their preparation
EP2042161A1 (en) * 1997-10-01 2009-04-01 Novadel Pharma Inc. Propellant-free spray composition comprising anti-emetic agent
SE9801495D0 (sv) * 1998-04-28 1998-04-28 Astra Ab Protein formulationa
US6531648B1 (en) * 1998-12-17 2003-03-11 Syngenta Participations Ag Grain processing method and transgenic plants useful therein
EP1031347B1 (en) * 1999-01-27 2002-04-17 Idea Ag Transnasal transport/immunisation with highly adaptable carriers
SE9904121D0 (sv) * 1999-11-15 1999-11-15 Gustaf Jederstroem Hydrophobe biomolecular structure
US6531112B2 (en) * 2000-05-15 2003-03-11 Delrx Pharmaceutical Corporation Formulations for administering calcitonin and processes for preparing the same
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US7316819B2 (en) * 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
CN1335182A (zh) * 2001-08-08 2002-02-13 华中科技大学 胰岛素口腔喷剂及其制备工艺
GB0119859D0 (en) * 2001-08-15 2001-10-10 Qinetiq Ltd Eye tracking system
US20060258561A1 (en) * 2003-03-13 2006-11-16 Novo Nordisk A/S Novel NPH insulin preparations
KR100638041B1 (ko) * 2003-12-24 2006-10-23 주식회사 삼양사 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법
EP1765406A4 (en) * 2004-05-21 2012-11-28 Mediplex Corp ADDITIVES FOR IMPROVED MUCOSAL ABSORPTION OF THERAPEUTIC AGENTS
CN105801686B (zh) * 2004-07-19 2020-04-07 比奥孔有限公司 胰岛素-低聚物共轭物、制剂及其用途
AU2005271526B2 (en) * 2004-08-03 2011-12-08 Emisphere Technologies, Inc. Antidiabetic oral insulin-biguanide combination
EP3391876B1 (en) 2005-05-23 2021-03-10 SDG, Inc. Lipid construct for delivery of insulin to a mammal
US20090098205A1 (en) * 2005-09-15 2009-04-16 Council Of Scientife & Industrial Research pH SENSITIVE NANOPARTICLE FORMULATION FOR ORAL DELIVERY OF PROTEINS/PEPTIDES
EP1957113A4 (en) * 2005-11-21 2011-11-09 Medivas Llc POLYMER PARTICLES FOR THE OUTPUT OF MACROMOLECULES AND METHOD OF APPLICATION THEREFOR
WO2007121318A2 (en) * 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin

Also Published As

Publication number Publication date
AU2008345474A1 (en) 2009-07-09
JP2011506587A (ja) 2011-03-03
IL206364A0 (en) 2010-12-30
US20090176691A1 (en) 2009-07-09
FR2925333A1 (fr) 2009-06-26
KR20150132887A (ko) 2015-11-26
US8309123B2 (en) 2012-11-13
BRPI0821373A2 (pt) 2015-06-16
CA2709899A1 (fr) 2009-07-09
CA2709899C (fr) 2018-01-16
WO2009083686A1 (fr) 2009-07-09
EP2234598A1 (fr) 2010-10-06
HK1146386A1 (en) 2011-06-03
TWI461226B (zh) 2014-11-21
CN101917967B (zh) 2013-05-22
KR101592609B1 (ko) 2016-02-05
AR069847A1 (es) 2010-02-24
WO2009083686A9 (fr) 2009-10-15
MX2010006927A (es) 2010-12-06
MA31927B1 (fr) 2010-12-01
AU2008345474B2 (en) 2014-07-31
AP2010005298A0 (en) 2010-06-30
JP5676272B2 (ja) 2015-02-25
TN2010000290A1 (fr) 2011-11-11
EA023107B1 (ru) 2016-04-29
FR2925333B1 (fr) 2012-04-13
KR20100095449A (ko) 2010-08-30
AP3573A (en) 2016-02-08
TW200940107A (en) 2009-10-01
EA201070746A1 (ru) 2011-02-28
BRPI0821373B1 (pt) 2020-04-22
CN101917967A (zh) 2010-12-15
IL206364A (en) 2016-12-29

Similar Documents

Publication Publication Date Title
BRPI0821373B8 (pt) composições farmacêuticas contendo ao menos um princípio ativo protéico protegido de enzimas digestivas
RS52913B (en) SUBcutaneous FORMULATION OF ANTI-HER2 ANTIBODIES
GT200600520A (es) Agentes antibacterianos
MY157860A (en) Prevention and treatment of secondary infections following viral infection
GB2483815A (en) Composition comprising oil drops
MX2009006033A (es) Composiciones y articulos que contienen una matriz de polimero reticulado y un liquido activo inmovilizado, asi como metodos para fabricarlos.
MX2008007307A (es) Granulos/capsulas modificados que contienen ingrediente activo.
WO2008036932A3 (en) Compositions and methods comprising boswellia species
CR9949A (es) Inhibidores de proteina activadora de la 5-lipoxigenasa (flap)
WO2007122581A3 (en) Compositions and kits of phenylephrine
EA200970081A1 (ru) Соединения, обладающие потенциирующим действием в отношении активности этионамида, и их применения
WO2008049042A3 (en) Ophthalmic compositions containing diglycine
WO2008108830A8 (en) Immunogenic and therapeutic compositions for streptococcus pyogenes
CL2013001482A1 (es) Compuestos derivados de 3-metil-7-oxo-4-tia-1-aza-biciclo[3.2.0]heptano para utilizarse en la inhibicion de beta-lactamasas producidas por bacterias y restaurar/potenciar la actividad de antibioticos; y composicion farmaceutica que los comprende.
ATE507214T1 (de) Neuartige serotonin-wiederaufnahmehemmer als arzneimittel mit peripheriesystem-beschränkter aktivität
WO2011153460A3 (en) Therapeutic amoeba and uses thereof
BRPI0909211B8 (pt) formulação oral em forma de comprimido de compostos de tetraciclina
GT200600512A (es) Enzimas para reducir el estres inmunologico
EP2557938A4 (en) PROTECTED ALPHA-AMYLASE
NO20082848L (no) Farmasoytisk formulering for behandling av osteoartritt inneholdende klodronsyre og hyaluronsyre
WO2012061360A3 (en) Pharmaceutical compositions
BRPI0817127A2 (pt) sistema desinfetante de evaporação diferencial potencializada
MX2009005329A (es) Composiciones farmaceuticas anticonvulsivas.
WO2005086669A3 (en) Hydrogenase deficient bacterial strains
WO2008015202A3 (en) Anticonvulsive pharmaceutical compositions

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/04/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/12/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF